Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized Phase III Trial of Cisplatin Plus Paclitaxel With and Without NCI-Supplied Bevacizumab (NSC #704865) Versus the Non-platinum Doublet, Topotecan Plus Paclitaxel, With and Without NCI-Supplied Bevacizumab, in Stage IVB, Recurrent or Persistent Carcinoma of the Cervix
Brief Summary: This randomized phase III trial studies the side effects of paclitaxel when given together with cisplatin or topotecan with or without bevacizumab and to compare how well they work in treating patients with stage IVB, cervical cancer that has come back or is persistent. Drugs used in chemotherapy, such as paclitaxel, cisplatin, and topotecan, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Monoclonal antibodies, such as bevacizumab, may interfere with the ability of tumor cells to grow and spread. It is not yet known whether paclitaxel is more effective when given together with cisplatin or topotecan with or without bevacizumab in treating patients with cervical cancer.


Options:
A: Arm Label: I; Type: EXPERIMENTAL; Interventions: Drug: Topotecan, Drug: Cisplatin, Drug: Bevacizumab | Intervention Type: DRUG; Name: Topotecan; Assigned to Arm(s): I | Intervention Type: DRUG; Name: Cisplatin; Assigned to Arm(s): I | Intervention Type: DRUG; Name: Bevacizumab; Assigned to Arm(s): I
B: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: chemotherapy: Paclitaxel/Cisplatin | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: chemotherapy: Paclitaxel/Carboplatin | Intervention Type: DRUG; Name: chemotherapy: Paclitaxel/Cisplatin; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: chemotherapy: Paclitaxel/Carboplatin; Assigned to Arm(s): 2
C: Arm Label: Arm I (paclitaxel and cisplatin); Type: ACTIVE_COMPARATOR; Interventions: Drug: Cisplatin, Other: Laboratory Biomarker Analysis, Drug: Paclitaxel, Other: Quality-of-Life Assessment, Other: Questionnaire Administration | Arm Label: Arm II (paclitaxel, cisplatin, bevacizumab); Type: EXPERIMENTAL; Interventions: Biological: Bevacizumab, Drug: Cisplatin, Other: Laboratory Biomarker Analysis, Drug: Paclitaxel, Other: Quality-of-Life Assessment, Other: Questionnaire Administration | Arm Label: Arm III (topotecan hydrochloride and paclitaxel); Type: EXPERIMENTAL; Interventions: Other: Laboratory Biomarker Analysis, Drug: Paclitaxel, Other: Quality-of-Life Assessment, Other: Questionnaire Administration, Drug: Topotecan Hydrochloride | Arm Label: Arm IV (topotecan hydrochloride, paclitaxel, bevacizumab); Type: EXPERIMENTAL; Interventions: Biological: Bevacizumab, Other: Laboratory Biomarker Analysis, Drug: Paclitaxel, Other: Quality-of-Life Assessment, Other: Questionnaire Administration, Drug: Topotecan Hydrochloride | Intervention Type: BIOLOGICAL; Name: Bevacizumab; Assigned to Arm(s): Arm II (paclitaxel, cisplatin, bevacizumab), Arm IV (topotecan hydrochloride, paclitaxel, bevacizumab) | Intervention Type: DRUG; Name: Cisplatin; Assigned to Arm(s): Arm I (paclitaxel and cisplatin), Arm II (paclitaxel, cisplatin, bevacizumab) | Intervention Type: OTHER; Name: Laboratory Biomarker Analysis; Assigned to Arm(s): Arm I (paclitaxel and cisplatin), Arm II (paclitaxel, cisplatin, bevacizumab), Arm III (topotecan hydrochloride and paclitaxel), Arm IV (topotecan hydrochloride, paclitaxel, bevacizumab) | Intervention Type: DRUG; Name: Paclitaxel; Assigned to Arm(s): Arm I (paclitaxel and cisplatin), Arm II (paclitaxel, cisplatin, bevacizumab), Arm III (topotecan hydrochloride and paclitaxel), Arm IV (topotecan hydrochloride, paclitaxel, bevacizumab) | Intervention Type: OTHER; Name: Quality-of-Life Assessment; Assigned to Arm(s): Arm I (paclitaxel and cisplatin), Arm II (paclitaxel, cisplatin, bevacizumab), Arm III (topotecan hydrochloride and paclitaxel), Arm IV (topotecan hydrochloride, paclitaxel, bevacizumab) | Intervention Type: OTHER; Name: Questionnaire Administration; Assigned to Arm(s): Arm I (paclitaxel and cisplatin), Arm II (paclitaxel, cisplatin, bevacizumab), Arm III (topotecan hydrochloride and paclitaxel), Arm IV (topotecan hydrochloride, paclitaxel, bevacizumab) | Intervention Type: DRUG; Name: Topotecan Hydrochloride; Assigned to Arm(s): Arm III (topotecan hydrochloride and paclitaxel), Arm IV (topotecan hydrochloride, paclitaxel, bevacizumab)
D: Arm Label: Arm A; Type: ACTIVE_COMPARATOR; Interventions: Drug: Bevacizumab, Drug: Cisplatin/Carboplatin, Drug: Paclitaxel | Arm Label: Arm B; Type: EXPERIMENTAL; Interventions: Drug: Atezolizumab, Drug: Bevacizumab, Drug: Cisplatin/Carboplatin, Drug: Paclitaxel | Intervention Type: DRUG; Name: Atezolizumab; Assigned to Arm(s): Arm B | Intervention Type: DRUG; Name: Bevacizumab; Assigned to Arm(s): Arm A, Arm B | Intervention Type: DRUG; Name: Cisplatin/Carboplatin; Assigned to Arm(s): Arm A, Arm B | Intervention Type: DRUG; Name: Paclitaxel; Assigned to Arm(s): Arm A, Arm B

Answer: C